HASBROUCK HEIGHTS, N.J., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2012. Nymox reported a net loss of $1,245,563, or $0.04 per share, for the quarter and $4,813,666, or $0.15 per share, for the nine months ended September 30, 2012, compared to $1,614,041, or $0.05 per share, for the quarter and $7,993,264, or $0.24 per share, for the nine months ended September 30, 2011. Net losses include stock-based compensation charges of $294,945 for the nine months ended September 30, 2012 and $3,943,338 in the comparative period in 2011. The decrease in net losses is attributable primarily to lower stock-based compensation charges in 2012 compared to 2011.
